These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 19191085

  • 1. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S, Kjeldsen SE, Hedner T, Narkiewicz K.
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract] [Full Text] [Related]

  • 2. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL, Atar D, Hanley DF.
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract] [Full Text] [Related]

  • 3. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun 29; 148(26):50-1. PubMed ID: 16875381
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A, Baliga V, TRIUMPH Study Group.
    J Indian Med Assoc; 2008 Mar 29; 106(3):191-4, 196. PubMed ID: 18712142
    [Abstract] [Full Text] [Related]

  • 5. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J.
    Cardiovasc J Afr; 2011 Mar 29; 22(4):224. PubMed ID: 21881697
    [No Abstract] [Full Text] [Related]

  • 6. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M.
    Dtsch Med Wochenschr; 2012 Nov 29; 137(48):2498. PubMed ID: 23168983
    [No Abstract] [Full Text] [Related]

  • 7. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
    Nilsson PM.
    Lakartidningen; 2012 Nov 29; 105(19):1382-4. PubMed ID: 18574975
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF, Tobe S, Teo KK, Yusuf S.
    Nephrol Dial Transplant; 2010 Jan 29; 25(1):42-4. PubMed ID: 19854846
    [No Abstract] [Full Text] [Related]

  • 10. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu LS.
    Chin Med J (Engl); 2011 Jun 29; 124(12):1763-8. PubMed ID: 21740829
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF, ONTARGET and TRANSCEND Investigators.
    Circulation; 2011 Mar 15; 123(10):1098-107. PubMed ID: 21357827
    [Abstract] [Full Text] [Related]

  • 12. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.
    Eur J Prev Cardiol; 2014 Mar 15; 21(3):299-309. PubMed ID: 24191305
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Burnier M, Waeber B, Hess O, Lüscher T.
    Praxis (Bern 1994); 2008 May 14; 97(10):559-62. PubMed ID: 18595371
    [No Abstract] [Full Text] [Related]

  • 14. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators.
    Lancet; 2008 Aug 16; 372(9638):547-53. PubMed ID: 18707986
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P, Remuzzi G.
    Nat Rev Nephrol; 2009 Aug 16; 5(8):436-7. PubMed ID: 19639016
    [No Abstract] [Full Text] [Related]

  • 17. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M, Böhm M.
    Expert Opin Pharmacother; 2009 Dec 16; 10(18):3113-7. PubMed ID: 19925045
    [Abstract] [Full Text] [Related]

  • 18. ONTARGET should not be over interpreted.
    Abutaleb N.
    Nephrol Dial Transplant; 2010 Jan 16; 25(1):44-7. PubMed ID: 19934088
    [No Abstract] [Full Text] [Related]

  • 19. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN.
    Nat Clin Pract Cardiovasc Med; 2008 Sep 16; 5(9):526-7. PubMed ID: 18665135
    [Abstract] [Full Text] [Related]

  • 20. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008 Sep 16; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.